Genmab Makes $8 Billion Bet On Merus With Potential Cancer Breakthrough
This Dutch Drugmaker's Stock Is Jumping 38%. Here's Why It's Being Acquired.
Months after cancer drug trial, Merus agrees to be bought at 41% premium
Genmab to buy Dutch cancer drugmaker Merus for $8 billion